Does heaven exist? With well over 100,000 plus recorded and described spiritual experiences collected over 15 years, to base the answer on, science can now categorically say yes. Furthermore, you can see the evidence for free on the website allaboutheaven.org.

Available on Amazon
also on all local Amazon sites, just change .com for the local version (.co.uk, .jp, .nl, .de, .fr etc.)


This book, which covers Visions and hallucinations, explains what causes them and summarises how many hallucinations have been caused by each event or activity. It also provides specific help with questions people have asked us, such as ‘Is my medication giving me hallucinations?’.

Available on Amazon
also on all local Amazon sites, just change .com for the local version (.co.uk, .jp, .nl, .de, .fr etc.)

Observations placeholder

Torisel hallucinations



Type of Spiritual Experience


Number of hallucinations: 18


The mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase that regulates cell growth, cell proliferation, cell motility, cell survival, protein synthesis, and transcription.

TOR was first discovered in yeast J.N. Heitman, N.R. Movva and M.N. Hall [Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast, Science 253 (1991)].  It was designated as mTOR, the mammalian target of rapamycin. The binding of immunosuppressant drugs like rapamycin and umirolimus to mTOR is thought to block mTOR's crucial role in these cellular events, resulting in arrest of the cell cycle, and ultimately, cell proliferation.

We can thus see that any drug within this category has a role in suppressing cancer cells.  A quote from Wikipedia, probably as baffling to you as it was to me

Drugs in this category inhibit cell proliferation by actions which occur downstream of growth factor binding. The signal transduction events which culminate in cell cycle arrest in the G1 phase are initiated as a result of ligand binding to an immunophilin known as FK binding protein-12. Subsequent investigations showed that rapamycin binds to this intracellular target, forming an FKBP12–rapamycin complex which is not in itself inhibitory, but does have the capacity to block the integral protein kinase target of rapamycin (TOR)”.

If the mTOR kinase is inhibited, the cell no longer produces the key proteins needed for proliferation, growth, survival, and angiogenesis.  This is how it helps in cancer arrest, as cancer cells slow down or are even halted in their out of control proliferation.  mTOR is activated in tumor cells by various mechanisms including growth factor surface receptor tyrosine kinases, oncogenes, and loss of tumor suppressor genes, so the causes aren’t really addressed using these drugs, only the effects.

The number of hallucinations produced is relatively small –  but this may be because they aren't used much.  I have added them in, however,  for completeness sake.

A description of the experience


is sold as Torisel.  It is an intravenous drug for the treatment of renal cell carcinoma (RCC), and was approved by the FDA and EMEA in 2007. Temsirolimus is a specific inhibitor of mTOR and interferes with the synthesis of proteins that regulate proliferation, growth, and survival of tumor cells.

'In an international three-arm phase III study with 626 previously untreated, poor-prognosis patients, temsirolimus, interferon-α and the combination of both agents was compared. Median overall survival improved significantly in the temsirolimus group (10.9 months) compared with interferon-α group (7.3 months) and the combination group (8.4 months).  The toxicity profile is based on what was found in the phase III trial'.

Side effects

  • adverse reaction – fatigue; skin rash; stomatitis
  • hematologic abnormalities  - hemoglobin decreased; lymphocytes decreased
  • laboratory abnormalities - triglycerides increased; glucose increased; phosphorus decreased

Temsirolimus is associated with lung toxicity, and the risk of developing this complication may be increased among subjects with abnormal pre-treatment pulmonary functions or history of lung disease. 

On Dec, 05, 2016  2,792 people reported to have side effects when taking Torisel.
Among them, 18 people (0.64%) have Hallucination.


Time on Torisel when people have Hallucination  :

  < 1 month 1 - 6 months 6 - 12 months 1 - 2 years 2 - 5 years 5 - 10 years 10+ years
Hallucination 40.00% 60.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Age of people who have Hallucination when taking Torisel  :

  0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Hallucination 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 28.57% 71.43%


On Jun, 8, 2015: 2,078 people reported to have side effects when taking Torisel. Among them, 95 people (4.57%) have Death.


Time on Torisel when people have Death  :

  < 1 month 1 - 6 months 6 - 12 months 1 - 2 years 2 - 5 years 5 - 10 years 10+ years
Death 50.00% 33.33% 16.67% 0.00% 0.00% 0.00% 0.00%

Age of people who have Death when taking Torisel * :

  0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Death 0.00% 0.00% 0.00% 1.82% 1.82% 7.27% 9.09% 80.00%

The source of the experience


Concepts, symbols and science items



Science Items

Activities and commonsteps